Myelodysplastic Syndrome (MDS)
Oncology·MeSH: Myelodysplastic Syndromes
Prevalence
5.0 / 100K
9 drugs in development·9 companies·4 clinical trials
Drug Pipeline by Phase
Approved(2)
Phase 2(1)
| Drug | Company |
|---|---|
| abv-1702 | ABVC BIOPHARMA, INC. (ABVC) |
Phase 1(3)
Preclinical(1)
| Drug | Company |
|---|---|
| gtb-3550 | GT Biopharma, Inc. (GTBP) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| r289 | RIGEL PHARMACEUTICALS INC (RIGL) |
Phase 2/Phase 3(1)
Compare drugs
Frequently asked questions
How many drugs are in development for Myelodysplastic Syndrome (MDS)?
BioSniper tracks 9 drugs in development for Myelodysplastic Syndrome (MDS) across 9 companies.
How many clinical trials target Myelodysplastic Syndrome (MDS)?
There are 4 clinical trials targeting Myelodysplastic Syndrome (MDS) tracked by BioSniper.
What is the prevalence of Myelodysplastic Syndrome (MDS)?
The estimated prevalence of Myelodysplastic Syndrome (MDS) is approximately 5.0 per 100,000 population.
Deep-dive into Myelodysplastic Syndrome (MDS)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis